



Current Status of the Polish Journal of Neurology & Neurosurgery (Neurologia i Neurochirurgia Polska)

Recently, Clarivate Analytics released its 2018 InCites Journal Citation Reports™, and Elsevier's Scopus its 2018 CiteScore™ reports. We are very pleased to share with you our ranking status. The 2018 Impact Factor (IF) for the Polish Journal of Neurology and Neurosurgery (Neurologia i Neurochirurgia Polska) is 1.006, and the 2018 CiteScore (CS) is 0.99. Our 2017 IF was 0.817, and our 2017 CS was 0.96; therefore, both publication metrics have improved for 2018.

For the calculation period for the IF, 175 manuscripts have been cited. Our 5 most cited articles (1–5) deal with different aspects of neurology, including epilepsy, stroke, migraine, and others.

The majority of our articles included in the calculation scores were submitted by Polish authors. Authors from 4 other countries, Turkey, Italy, USA, and China, were listed in the first five positions.

Polish institutions with which the authors of the most cited papers are associated include the Medical University of Warsaw (Warsaw, Poland), Medical University of Silesia (Katowice, Poland), Jagiellonian University (Krakow, Poland), Institute of Psychiatry and Neurology (Warsaw, Poland), and Medical University of Lodz (Lodz, Poland). From outside of Poland, we have received articles from Mayo Clinic (Jacksonville, FL, USA), Rudolfstiftung Hospital (Vienna, Austria), Capital Medical University (Beijing, Peoples Republic of China), Kobe University, Grad. Sch. Med. (Kobe, Japan), and many others.

Clarivate Analytics IF is a result of mathematical calculations taking into consideration number of published articles in previous 2 years (2016 and 2017) and number of cited articles in the last year (2018): $IF = \frac{\text{Citations in 2018 to items published in 2016 + 2017}}{\text{number of citable items in 2016 + 2017}}$.

Elsevier's CS is calculated for three years according to the following formula: $CS = \frac{\text{Citation Count 2018}}{\text{Documents 2015–2017}}$. CS includes all available document types.

We very much thank our Readers, Authors, and Reviewers for their support of our Journal. We are grateful to our Readers sharing with us their comments regarding further improvements to the journal activities and status. We are extremely grateful to our Authors for submitting to us their best manuscripts. We are also very much grateful and indebted to our Journal Reviewers for their work and expertise. We appreciate the guidance that we have received from our Editorial Board members. We hope to improve the administrative operations of our Journal further, including reducing the time required to review and publish the papers submitted to us.

The Journal's success is your success!

Zbigniew K. Wszolek, M.D.

Co-Editor-in-Chief

Jaroslaw Slawek, M.D., Ph.D.

Co-Editor-in-Chief

Mariusz Sieminski, M.D., Ph.D.

Managing editor

References

1. Harat M, Rudaś M, Zieliński P, et al. Nucleus accumbens stimulation in pathological obesity. *Neurol Neurochir Pol.* 2016; 50(3): 207–210, doi: [10.1016/j.pjnns.2016.01.014](https://doi.org/10.1016/j.pjnns.2016.01.014), indexed in Pubmed: [27154450](https://pubmed.ncbi.nlm.nih.gov/27154450/).
2. Stöllberger C, Finsterer J. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. *Neurol Neurochir Pol.* 2017; 51(2): 194–196, doi: [10.1016/j.pjnns.2017.01.010](https://doi.org/10.1016/j.pjnns.2017.01.010), indexed in Pubmed: [28215696](https://pubmed.ncbi.nlm.nih.gov/28215696/).
3. Siuda J, Patalong-Ogięwa M, Żmuda W, et al. Cognitive impairment and BDNF serum levels. *Neurol Neurochir Pol.* 2017; 51(1): 24–32, doi: [10.1016/j.pjnns.2016.10.001](https://doi.org/10.1016/j.pjnns.2016.10.001), indexed in Pubmed: [28341039](https://pubmed.ncbi.nlm.nih.gov/28341039/).
4. Kotłęga D, Peda B, Zembroń-Lacny A, et al. The role of brain-derived neurotrophic factor and its single nucleotide polymorphisms in stroke patients. *Neurol Neurochir Pol.* 2017; 51(3): 240–246, doi: [10.1016/j.pjnns.2017.02.008](https://doi.org/10.1016/j.pjnns.2017.02.008), indexed in Pubmed: [28291539](https://pubmed.ncbi.nlm.nih.gov/28291539/).
5. Kuzawińska O, Lis K, Cessak G, et al. Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment. *Neurol Neurochir Pol.* 2016; 50(6): 463–467, doi: [10.1016/j.pjnns.2016.07.012](https://doi.org/10.1016/j.pjnns.2016.07.012), indexed in Pubmed: [27553188](https://pubmed.ncbi.nlm.nih.gov/27553188/).